Metagenomi Therapeutics (MGX) Cash from Investing Activities (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Cash from Investing Activities for 4 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 83.88% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $82.8 million (up 164.47% YoY), while the FY2025 annual figure was $103.5 million, up 217.44% from the prior year.
• Cash from Investing Activities eased to $4.0 million in Q1 2026 per MGX's latest filing, from $32.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $75.9 million in Q3 2023 and bottomed at -$94.7 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged $5.0 million across 4 years, with a median of $19.1 million in 2025.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities slumped 111.77% — and 2025, when it soared 406.28%.
• Metagenomi Therapeutics' Cash from Investing Activities stood at $60.6 million in 2023, then tumbled by 52.92% to $28.5 million in 2024, then climbed by 13.39% to $32.4 million in 2025, then sank by 87.68% to $4.0 million in 2026.
• Business Quant data shows MGX's Cash from Investing Activities at $4.0 million in Q1 2026, $32.4 million in Q4 2025, and $27.4 million in Q3 2025.